An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates

The mRNA vaccine technology has promising applications to fight infectious diseases as demonstrated by the licensing of two mRNA-based vaccines, Comirnaty (R) (Pfizer/BioNtech) and Spikevax (R) (Moderna), in the context of the Covid-19 crisis. Safe and effective delivery systems are essential to the performance of these vaccines and lipid nanoparticles (LNPs) able to entrap, protect and deliver the mRNA in vivo are considered by many as the current best in class . Nevertheless, current mRNA/LNP vaccine technology has still some limitations, one of them being thermostability, as evidenced by the ultracold distribution chain required for the licensed vaccines. We found that the thermostability of mRNA/LNP, could be improved by a novel imidazole modified lipid, DOGIM4, in combination with standard helper lipids. DOG-IM4 comprises an ionizable head group consisting of imidazole, a dioleoyl lipid tail and a short flexible polyoxyethylene spacer between the head and tail. Here we describe the synthesis of DOG-IM4 and show that DOG-IM4 LNPs confer strong immunization properties to influenza HA mRNA in mice and macaques and a remarkable stability to the encapsulated mRNA when stored liquid in phosphate buffered saline at 4 degrees C. We speculate the increased stability to result from some specific attributes of the lipid's imidazole head group.

Automated summary

mRNA vaccine technology has great potential in fighting infectious diseases, as shown by the licensing of Comirnaty (R) (Pfizer/BioNtech) and Spikevax (R) (Moderna), two mRNA-based vaccines, during the Covid-19 crisis. However, current mRNA/LNP vaccine technology has limitations, including thermostability. A novel imidazole modified lipid, DOGIM4, combined with standard helper lipids, can improve the thermostability of mRNA/LNP.